Royalty Report: Drugs, Disease, Arthritis – Collection: 210065


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Arthritis
  • Therapeutic
  • Orthopedic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 210065

License Grant
The Belgium Licensor granted the China Licensee an exclusive, royalty-bearing license to develop and commercialize the anti-TNF alpha Nanobody, ozoralizumab, and certain other anti-TNF alpha Nanobodies in Greater China for all indications, including rheumatiod arthritis.
License Property
The Licensors anti-TNF alpha Nanobody, ozoralizumab, targets RA, a progressive inflammatory disease of the joints and surrounding tissues.
Field of Use
The Licensee will be responsible for the registration and commercialization in Greater China of licensed products.

IPSCIO Record ID: 210030

License Grant
The Belgium Licensor entered into an exclusive license agreement with Japanese Licensee for the development and commercialization of anti-TNF alpha Nanobody, ozoralizumab, for the treatment of RA in Japan. The Licensee will be responsible for the development, registration and commercialization of ozoralizumab.
License Property
Ozoralizumab is a TNF alpha blocker being developed for the treatment of auto-immune disorders with an initial focus on RA.
Field of Use
The Japanese Licensee is planning to initiate a Phase III trial in RA patients in Japan with ozoralizumab in 2018.

IPSCIO Record ID: 210064

License Grant
The Belgium Licensor granted an exclusive, royalty-bearing license to the Chinese Licensee. The Licensee will develop and commercialize the anti-RANKL Nanobody, ALX-0141, in the People’s Republic of China, Hong Kong, Macao and Taiwan for the treatment of a range of diseases, including osteoporosis and bone metastases.
License Property
The Licensors anti-RANKL Nanobody, ALX-0141 is used in the treatment of bone loss disorders.
Field of Use
The Licensee is responsible for the clinical development, registration and commercialization of anti-RANKL Nanobody therapeutics.

IPSCIO Record ID: 227285

License Grant
The English parties agree to a collaboration for the further development, manufacture and commercialization of the Product initially for the treatment of rheumatoid arthritis (‘RA’) and Crohn’s disease in humans and for the treatment of any other agreed indications in the Field.  The co-exclusive collaboration includes the right to appoint any third party including but not limited to affiliated companies as distributors, except for Japan where Licensee shall have the right to appoint sub-licensees.
License Property
Product means Licensor’s anti-TNFµ compound known as CDP-870 in any formulation and indication.
Field of Use
The licence is exclusive for rheumatoid arthritis and other indications, excluding Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.